Fastly Shares Drop On Rating Downgrade: Read To Know
RBC Capital analyst Rishi Jaluria downgraded Fastly, Inc (NYSE:FSLY) to Underperform from Sector Perform with a price target of $9 (22% downside), down…
RBC Capital Downgrades Asana On Challenging Macro, Cash Burn Concerns
RBC Capital analyst Rishi Jaluria downgrades Asana, Inc (NYSE:ASAN) to Underperform from Sector Perform with a price target of $13 (23% downside), down…
Wolfe Research Downgrades Innovative Ind Props to Peer Perform
Wolfe Research analyst Andrew Rosivach downgrades Innovative Ind Props (NYSE:IIPR) from Outperform to Peer Perform.
BWS Financial Downgrades Tuesday Morning to Neutral, Announces $0.5 Price Target
BWS Financial analyst Hamed Khorsand downgrades Tuesday Morning (NASDAQ:TUEM) from Buy to Neutral and announces $0.5 price target.
B of A Securities Downgrades Pioneer Natural Resources to Underperform, Lowers Price Target to $244
B of A Securities analyst Doug Leggate downgrades Pioneer Natural Resources (NYSE:PXD) from Neutral to Underperform and lowers the price target from $272 to $244.
B of A Securities Downgrades Denbury to Underperform, Announces $71 Price Target
B of A Securities analyst Doug Leggate downgrades Denbury (NYSE:DEN) from Neutral to Underperform and announces $71 price target.
B of A Securities Downgrades California Resources to Underperform, Announces $49 Price Target
B of A Securities analyst Doug Leggate downgrades California Resources (NYSE:CRC) from Buy to Underperform and announces $49 price target.
Benchmark Downgrades Invitae to Hold
Benchmark analyst Bruce Jackson downgrades Invitae (NYSE:NVTA) from Buy to Hold.
Needham Downgrades Viavi Solutions to Hold
Needham analyst Alex Henderson downgrades Viavi Solutions (NASDAQ:VIAV) from Buy to Hold.
HC Wainwright Downgrades Angion Biomedica
Last month, Angion Biomedica Corp (NASDAQ:ANGN) discontinued the JUNIPER Phase 2 dose-finding trial of ANG-3070 in primary proteinuric kidney diseases, specifically focal…